P1-2 COST-EFFECTIVENESS OF ROUTINE USE OF MAGNESIUM SULFATE FOR SEIZURE PROPHYLAXIS IN MILD PREECLAMPSIA,
P3-7 CENTERING PREGNANCY FOR THE PREVENTION OF PRETERM BIRTH: A COST-EFFECTIVENESS ANALYSIS,
P3-48 TIMING DELIVERY OF PLACENTA ACCRETA: A DECISION ANALYSIS,
P4-31 TREATING PATIENTS IN HAPO GLUCOSE CATEGORY 5 TO IMPROVE MATERNAL AND NEONATAL OUTCOMES: A COST EFFECTIVENESS ANALYSIS,
P4-53 REDUCING TRIPLET GESTATIONS: A DECISION ANALYSIS
P3-7 CENTERING PREGNANCY FOR THE PREVENTION OF PRETERM BIRTH: A COST-EFFECTIVENESS ANALYSIS,
P3-48 TIMING DELIVERY OF PLACENTA ACCRETA: A DECISION ANALYSIS,
P4-31 TREATING PATIENTS IN HAPO GLUCOSE CATEGORY 5 TO IMPROVE MATERNAL AND NEONATAL OUTCOMES: A COST EFFECTIVENESS ANALYSIS,
P4-53 REDUCING TRIPLET GESTATIONS: A DECISION ANALYSIS
E-1 OPTIMAL INFORMATION ACQUISITION POLICY IN DYNAMIC HEALTHCARE POLICY: APPLICATION TO HCV SCREENING,
F-3 COMBINING REGRESSION ANALYSES AND MARKOV MODELS TO INFER AGE-SPECIFIC MORTALITY RATES BY HEPATITIS C INFECTION AND RISK FACTOR STATUS,
I-6 OPTIMAL HEALTH PROGRAM INTERVENTION AND INFORMATION ACQUISITION POLICY
F-3 COMBINING REGRESSION ANALYSES AND MARKOV MODELS TO INFER AGE-SPECIFIC MORTALITY RATES BY HEPATITIS C INFECTION AND RISK FACTOR STATUS,
I-6 OPTIMAL HEALTH PROGRAM INTERVENTION AND INFORMATION ACQUISITION POLICY